Diagnostic value of asprosin for sepsis: a case-control study in the emergency department

Asprosin is a polypeptide with versatile metabolic roles, peripherally and centrally, secreted mainly by white adipose tissue during fasting. High asprosin levels may be a risk factor for conditions such as obesity, diabetic nephropathy, and retinopathy and are positively associated with inflammatory markers. Our study aimed to investigate the predictive value of asprosin in diagnosing sepsis. The prospective case-controlled study included 80 individuals with a 1:1 ratio of sepsis and healthy individuals. Receiver operating characteristic curve (ROC) analysis was used to evaluate the diagnostic impact of asprosin on sepsis patients. The sepsis patients were 24 women and 16 men, with a median age of 73 years (Interquartile Range (IQR) 63–79). The control group included 40 healthy individuals, 24 women and 16 men, with a median age of 73 (IQR 63–79). While the asprosin level of the control group was 0.29 ng/mL, that of the sepsis group was 0.77 ng/mL (p < 0.001). When the cut-off value was accepted as 0.452, the sensitivity and specificity of asprosin were 85% and 80%. The area under the curve (AUC) of asprosin was found to be 0.904 (95% Confidence Interval (CI): 0.841–0.967, p < 0.001). In conclusion, higher asprosin levels were found in sepsis than in control patients, and asprosin had a high discriminatory ability diagnosis for sepsis.

FBN1 protein; Human; Sepsis; Biomarkers

[1] Norse AB, Guirgis F, Black LP, DeVos EL. Updates and controversies in the early management of sepsis and septic shock. Emergency Medicine Practice. 2021; 23: 1–24.

[2] World Health Organization. Global report on the epidemiology and burden of sepsis. 2020. Available at: https://www.who.int/publications-detail-redirect/9789240010789 (Accessed: 07 December 2023).

[3] Akkoç I, Sağlam Z, Şen Ö, Aydin N, Koldaş M, Toptaş M, et al. Efficacy of presepsin as a biomarker of sepsis and its prognostic value for prediction of mortality. Medical Bulletin of Haseki. 2020; 58: 200–207.

[4] Reddy V, Reddy H, Gemnani R, Kumar S, Acharya S. Navigating the complexity of scoring systems in sepsis management: a comprehensive review. Cureus. 2024; 16: e54030.

[5] Jeon E-T, Song J, Park DW, Lee K-S, Ahn S, Kim JY, et al. Mortality prediction of patients with sepsis in the emergency department using machine learning models: a retrospective cohort study according to the Sepsis-3 definitions. Signa Vitae. 2023; 19: 112–124.

[6] Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016; 165: 566–579.

[7] Shabir K, Brown JE, Afzal I, Gharanei S, Weickert MO, Barber TM, et al. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: comprehensive review of preclinical and clinical evidence. Cytokine & Growth Factor Reviews. 2021; 60: 120–132.

[8] Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nature Medicine. 2017; 23: 1444–1453.

[9] Huang Q, Chen S, Xiong X, Yin T, Zhang Y, Zeng G, et al. Asprosin exacerbates endothelium inflammation induced by hyperlipidemia through activating IKKβ-NF-κBp65 pathway. Inflammation. 2023; 46: 623–638.

[10] Kocaman N, Kuloğlu T. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue and Cell. 2020; 66: 101397.

[11] Salt SA, Aydoğdu N, Salt Ö, Fırat N, Süt N. The role of asprosin in the diagnosis of diabetic and non-diabetic patients with sepsis. Signa Vitae. 2024; 20: 40–45.

[12] Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Molecular and Cellular Endocrinology. 2019; 486: 96–104.

[13] Shabir K, Gharanei S, Orton S, Patel V, Chauhan P, Karteris E, et al. Asprosin exerts pro-inflammatory effects in THP-1 macrophages mediated via the toll-like receptor 4 (TLR4) pathway. International Journal of Molecular Sciences. 2022; 24: 227.

[14] Kilinc Toker A, Kose S, Turken M. Comparison of SOFA score, SIRS, qSOFA, and qSOFA + L criteria in the diagnosis and prognosis of sepsis. The Eurasian Journal of Medicine. 2021; 53: 40–47.

[15] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315: 801–810.

[16] Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Critical Care Medicine. 2003; 31: 1737–1741.

[17] Sharma B, Sharma M, Majumder M, Steier W, Sangal A, Kalawar M. Thrombocytopenia in septic shock patients—a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesthesia and Intensive Care. 2007; 35: 874–880.

[18] Donma MM, Donma O. Asprosin: possible target in connection with ghrelin and cytokine network expression in the post-burn treatment. Medical Hypotheses. 2018; 118: 163–168.

[19] Sipahioglu H, Sen O, Koyuncu S, Kuzugüden S. Serum asprosin level as a new biomarker in differentiating familial Mediterranean fever attacks. Cureus. 2023; 15: e35342.

[20] Mazur-Bialy AI. Asprosin enhances cytokine production by a co-culture of fully differentiated mature adipocytes and macrophages leading to the exacerbation of the condition typical of obesity-related inflammation. International Journal of Molecular Sciences. 2023; 24: 5745.

[21] Rogić D, Juroš GF, Petrik J, Vrančić AL. Advances and pitfalls in using laboratory biomarkers for the diagnosis and management of sepsis. The electronic Journal of IFCC. 2017; 28: 114–121.